Home >> Tag Archives: Illumina—

Tag Archives: Illumina—

Illumina to buy PacBio for $1.2 billion

Nov. 7, 2018—Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina’s short-read sequencing platforms with PacBio’s long-read sequencing capabilities to help researchers advance their discoveries faster and clinicians offer new tests economically. “PacBio’s unmatched accuracy mirrors that of Illumina’s ...

Read More »

Illumina launches TruSight Oncology 500

Nov. 1, 2018—Illumina  launched its TruSight Oncology 500, a comprehensive next-generation sequencing assay. TSO 500 uses DNA and RNA to identify multiple variant types, including small nucleotide variants, indels, splice variants, fusions, and tumor mutational burden and microsatellite instability from the same formalin-fixed, paraffin-embedded tumor sample. The panel contains 1.94 Mb of genomic content to measure TMB and offers sophisticated variant ...

Read More »

NextSeq 550Dx NGS system, 2/18

February 2018—Illumina introduced its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD-marked next-generation-sequencing system. Illumina also announced that the intended use for the MiSeqDx instrument now includes the use of DNA libraries generated from formalin-fixed, paraffin-embedded tissues.

Read More »

IIlumina’s iSeq 100, Thermo Fisher agreement

Jan. 11, 2018—Illumina announced Tuesday the launch of its iSeq 100 Sequencing System, a next-generation sequencing system that aims to deliver exceptional data accuracy at a low capital cost—the U.S. list price is $19,900. The system combines the company’s sequencing by synthesis chemistry and complementary metal-oxide-semiconductor detection technology and represents an entirely different configuration, the company said. “The addition of ...

Read More »

Whole genome sequencing library prep kit, 12/17

December 2017—Illumina announced the availability of a whole genome sequencing library prep product, Nextera DNA Flex. The kit enables direct input of blood and saliva samples, eliminating the need for ancillary equipment and reagents to extract DNA and quantify sample concentration prior to sequencing. It also removes steps in the library prep workflow, such as mechanical fragmentation of DNA, quantification, and normalization.

Read More »

First cancer CDx for Illumina

July 12, 2017—Illumina announced its Extended RAS Panel, an FDA-approved next-generation sequencing kit that meets the published guidelines for evaluation of colorectal cancer from the CAP, American Society for Clinical Pathology, Association for Molecular Pathology, and American Society of Clinical Oncology. This kit is intended to be used on the Illumina MiSeqDx system and enables U.S. laboratories to help clinicians ...

Read More »

Philips, Illumina to offer genomics solutions

Jan. 16, 2017—Royal Philips and Illumina announced a strategic collaboration that aims to integrate Illumina’s sequencing systems for large-scale analysis of genetic variation and function and Philips’ IntelliSpace Genomics clinical informatics platform and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the U.S. ...

Read More »

ArcherDx forms NGS partnerships

June 9, 2016—ArcherDx has announced two agreements related to its work in next-generation sequencing. Under terms of an agreement with Illumina, ArcherDx will lead the development of a series of diagnostic tests utilizing ArcherDx’s Anchored Multiplex PCR chemistry that will be run on the Illumina MiSeqDx instrument. This agreement reflects the commitment of both companies to provide NGS-based diagnostics to ...

Read More »
X